MX2024007064A - Metodos de administracion de un modulador de hemoglobina. - Google Patents

Metodos de administracion de un modulador de hemoglobina.

Info

Publication number
MX2024007064A
MX2024007064A MX2024007064A MX2024007064A MX2024007064A MX 2024007064 A MX2024007064 A MX 2024007064A MX 2024007064 A MX2024007064 A MX 2024007064A MX 2024007064 A MX2024007064 A MX 2024007064A MX 2024007064 A MX2024007064 A MX 2024007064A
Authority
MX
Mexico
Prior art keywords
methods
hemoglobin
modulator
administering
treatment
Prior art date
Application number
MX2024007064A
Other languages
English (en)
Spanish (es)
Inventor
Arthur Lo
Carla B Washington
Aline Barth
Ken Duchin
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of MX2024007064A publication Critical patent/MX2024007064A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024007064A 2021-12-10 2022-12-09 Metodos de administracion de un modulador de hemoglobina. MX2024007064A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163288377P 2021-12-10 2021-12-10
US202263421524P 2022-11-01 2022-11-01
US202263429376P 2022-12-01 2022-12-01
PCT/US2022/052411 WO2023107697A1 (en) 2021-12-10 2022-12-09 Methods of administering a modulator of hemoglobin

Publications (1)

Publication Number Publication Date
MX2024007064A true MX2024007064A (es) 2024-06-20

Family

ID=85108880

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007064A MX2024007064A (es) 2021-12-10 2022-12-09 Metodos de administracion de un modulador de hemoglobina.

Country Status (10)

Country Link
US (1) US20250041312A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444285A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024545496A (cg-RX-API-DMAC7.html)
KR (1) KR20240116826A (cg-RX-API-DMAC7.html)
AU (1) AU2022408097B2 (cg-RX-API-DMAC7.html)
CA (1) CA3241881A1 (cg-RX-API-DMAC7.html)
IL (1) IL312835A (cg-RX-API-DMAC7.html)
MX (1) MX2024007064A (cg-RX-API-DMAC7.html)
TW (1) TW202339732A (cg-RX-API-DMAC7.html)
WO (1) WO2023107697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023021606A2 (pt) * 2021-05-14 2023-12-19 Global Blood Therapeutics Inc Formas sólidas de modulador de hemoglobina
EP4727555A1 (en) * 2023-06-13 2026-04-22 Global Blood Therapeutics, Inc. (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
PT3880654T (pt) 2018-11-19 2022-04-08 Global Blood Therapeutics Inc Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina
BR112023021606A2 (pt) * 2021-05-14 2023-12-19 Global Blood Therapeutics Inc Formas sólidas de modulador de hemoglobina

Also Published As

Publication number Publication date
US20250041312A1 (en) 2025-02-06
WO2023107697A1 (en) 2023-06-15
JP2024545496A (ja) 2024-12-09
KR20240116826A (ko) 2024-07-30
CA3241881A1 (en) 2023-06-15
EP4444285A1 (en) 2024-10-16
AU2022408097A1 (en) 2024-05-30
AU2022408097B2 (en) 2026-03-12
IL312835A (en) 2024-07-01
TW202339732A (zh) 2023-10-16

Similar Documents

Publication Publication Date Title
CO2021006075A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
BR112022012130A2 (pt) Compostos antelmínticos compreendendo uma estrutura azaindólica
BR112022012126A2 (pt) Compostos antelmínticos compreendendo uma estrutura quinolínica
ECSP21093559A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
UY39150A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CL2024002763A1 (es) Dosificación no lineal de mirdametinib
AR089409A1 (es) Agente de control de enfermedades de las plantas
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
ECSP22007557A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
BR112021019876A2 (pt) Inibidores de pde9 para tratar anemia falciforme
CL2022003435A1 (es) Métodos de tratamiento del complejo de esclerosis tuberosa
ECSP10010249A (es) Tratamiento de cardiopatías usando -bloqueantes
BR112022004809A2 (pt) Compostos 2-amino-s6-tiopurina substituídos como inibidores da proteína enpp1
CL2023000261A1 (es) Métodos de tratamiento de la neuralgia del trigémino
ECSP23088732A (es) Moduladores de trex1
ECSP13012369A (es) Agentes terapéuticos 976
MX2022000426A (es) Telmisartan para el tratamiento de la hipertension en perros.
MX2022003628A (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.
AR128636A1 (es) Inhibidor de recaptación triple para el tratamiento de la depresión atípica
AR132243A1 (es) Agonistas heterocíclicos de glp-1
CO2026000989A2 (es) Nuevos compuestos de carboxamida-4-quinolina con actividad antihelmíntica